Russia’s Medical Biological Agency Has Developed 7 Vaccine Prototypes against COVID-19

| By | Development of Vaccines

“As of today, the Federal Medical Biological Agency has developed seven prototypes of a genetically engineered vaccine assembled from fused proteins, with each of them having epitopes, i.e. parts that interact with the virus,” the agency’s head, Veronika Skvortsova, said.

The current task, in her words, is to choose the most efficient vaccine prototypes from among these seven. “First it is done it the computer modelling regime. From Monday, it will be done at the Microbiology Center of the Russian defense ministry which is certified to work with bio pathogens of the second class,” she added.

She said however that a ready-to-use vaccine could be expected no earlier than in 11 months. “We plan to finish all tests by July and move on to pre-clinical trials. We plan to proceed to the first and second phase by the end of the current year – the first quarter of the next year,” she noted.

GMP news
Pharmaceutical industry News and events. Technology transfer and contract manufacturing of medicines.